Close
11-15

I-Mab Reports Third Quarter 2024 Results

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study ofuliledlimab in first-line mNSCLC in 1H 2025

Home Previous 74 75 76 77 78 79 80 Next Tail

10 Items Per Page (Page 77 / 151) Total 1503 Items

©copyright 2009-2020 Ritzaus Bureau      Contact Us   SiteMap